Tempus AI (TEM) stock surged 7% after BTIG raised its price target to $80 and Moderna's cancer trial win emphasized the value of TEM's Personalis deal. The post Tempus AI (TEM) Stock Surges 7% Following Price Target Hike and Personalis Deal Spotlight appeared first on Blockonomi.